In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model

被引:104
作者
Andes, D. [1 ,2 ]
Diekema, D. J.
Pfaller, M. A. [3 ]
Prince, R. A. [3 ,4 ]
Marchillo, K. [1 ]
Ashbeck, J. [1 ]
Hou, J. [4 ]
机构
[1] Univ Wisconsin, Dept Med, Madison, WI USA
[2] Univ Wisconsin, Dept Immunol & Med Microbiol, Madison, WI USA
[3] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA
[4] Univ Texas Houston, Sch Pharm, Houston, TX USA
关键词
INVASIVE PULMONARY ASPERGILLOSIS; AMPHOTERICIN-B; INTERPRETIVE BREAKPOINTS; CASPOFUNGIN RESISTANCE; REDUCED SUSCEPTIBILITY; ANTIFUNGAL AGENTS; ECHINOCANDIN-B; MICAFUNGIN; PHARMACOKINETICS; ALBICANS;
D O I
10.1128/AAC.01061-07
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Multiple in vivo studies have characterized the pharmacodynamics of drugs from the triazole and polyene antifungal drug classes. Fewer studies have investigated these pharmacodynamic relationships for the echinocandin drug class. We used a neutropenic murine model of disseminated Candida albicans, Candida tropicalis, and Candida glabrata infection to characterize the time course of activity of the new echinocandin anidulafungin. The pharmacokinetic-pharmacodynamic (PK-PD) indices (the percentage of time that the drug concentration was above the MIC, the ratio of the area under the concentration-time curve from 0 to 24 h [AUC(0-24)] to the MIC, and the ratio of the maximum serum drug concentration [C-max] to the MIC were correlated with in vivo efficacy, as measured by organism numbers in kidney cultures after 96 h of therapy. The kinetics following intraperitoneal anidulafungin dosing in neutropenic infected mice were monitored. Peak levels and AUCs were linear over the 16-fold dose range studied. The drug elimination half-life in serum ranged from 14 to 24 h. Single-dose postantifungal-effect studies demonstrated prolonged suppression of organism regrowth after serum anidulafungin levels had fallen below the MIC. Of the four dosing intervals studied, treatment with the more widely spaced dosing regimens was most efficacious, suggesting the C-max/MIC ratio as the PK-PD index most predictive of efficacy. Nonlinear regression analysis suggested that both the C-max/MIC and AUC/MIC ratios were strongly predictive of treatment success. Studies were then conducted with 13 additional C. albicans, C. tropicalis, and C. glabrata isolates with various anidulafungin susceptibilities (MICs of anidulafungin for these strains, 0.015 to 2.0 mu g/ml) to determine if similar C-max/MIC and AUC(0-24)/MIC ratios for these isolates were associated with efficacy. The anidulafungin exposures associated with efficacy were similar among Candida species.
引用
收藏
页码:539 / 550
页数:12
相关论文
共 54 条
[1]   Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore [J].
Ambrose, Paul G. ;
Bhavnani, Sujata M. ;
Rubino, Christopher M. ;
Louie, Arnold ;
Gumbo, Tawanda ;
Forrest, Alan ;
Drusano, George L. .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (01) :79-86
[2]   In vivo Fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling [J].
Andes, D. ;
Lepak, A. ;
Nett, J. ;
Lincoln, L. ;
Marchillo, K. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (07) :2384-2394
[3]   In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model [J].
Andes, D ;
Marchillo, K ;
Lowther, J ;
Bryskier, A ;
Stamstad, T ;
Conklin, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1187-1192
[4]   Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model [J].
Andes, D ;
van Ogtrop, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2116-2120
[5]   In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model [J].
Andes, D ;
van Ogtrop, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :938-942
[6]   In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis [J].
Andes, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1179-1186
[7]   Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model [J].
Andes, D ;
Stamsted, T ;
Conklin, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :922-926
[8]   In vivo pharmacodynamic activity of the glycopeptide dalbavancin [J].
Andes, David ;
Craig, William A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (05) :1633-1642
[9]   COMPARATIVE-STUDY WITH ENOXACIN AND NETILMICIN IN A PHARMACODYNAMIC MODEL TO DETERMINE IMPORTANCE OF RATIO OF ANTIBIOTIC PEAK CONCENTRATION TO MIC FOR BACTERICIDAL ACTIVITY AND EMERGENCE OF RESISTANCE [J].
BLASER, J ;
STONE, BB ;
GRONER, MC ;
ZINNER, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) :1054-1060
[10]   Micafungin: A new echinocandin [J].
Chandrasekar, PH ;
Sobel, JD .
CLINICAL INFECTIOUS DISEASES, 2006, 42 (08) :1171-1178